Call Us: 1.800.873.5297

By

Transvaginal Mesh Lawsuit Update: FDA Rejects Public Citizen’s Petition to Ban and Recall TVM Devices

The U.S. Food and Drug Administration (FDA) has issued its Final Response rejecting a 2011 Petition Filed by Public Citizen, a non-profit consumer advocacy organization, calling for a total ban and complete recall  of the Transvaginal Mesh® (TVM) devices used for the treatment of pelvic organ prolapse (POP). Public Citizen also petitioned the FDA to […]

By

Merck Canada Warns Against NuvaRing® Use in Certain Women

According to the Toronto Times Colonist, Merck Canada, Inc., the manufacturers of the contraceptive device NuvaRing®, is warning against NuvaRing® use in women who smoke and who are over the age of 35. Merck Canada met with the Health Canada Advisory Committee on July 31, 2014 to inform them of additional restrictions on NuvaRing® use. […]

By

Boston Scientific Transvaginal Mesh Lawsuits in Massachusetts State Court Move Forward After a Defense Verdict, Schlichter, Bogard & Denton Reports

Kristine Kraft, a partner at Schlichter, Bogard & Denton, LLP, reports that the Massachusetts state court trials involving transvaginal mesh (TVM) devices will move forward after a defense verdict in favor of Boston Scientific was rendered on July 29, 2014. (Albright v. Boston Scientific Corp., Case No. 12-909, Middlesex County Superior Court, Massachusetts). Following nearly […]

By

Ohio Governor Declares State of Emergency in Drinking Water Contamination Case

According to an ABC report, the Governor of Ohio has declared a state of emergency due to toxins contaminating the drinking water supply for approximately 11 million people. Toledo officials warned residents not to use city water after microcystin tests at one treatment plant showed that levels were above the standard for drinking water consumption. […]

By

Schlichter, Bogard & Denton, LLP News: Partner Kristine Kraft Appointed to the Plaintiffs’ Steering Committee in Testosterone Therapy MDL 2545

Kristine Kraft, a partner at Schlichter, Bogard & Denton, LLP, has been appointed to the Plaintiffs’ Steering Committee in the Low-T Multidistrict Litigation (MDL 2545) pending in the Northern District of Illinois (Case Management Order No. 4, In Re: Testosterone Therapy Products Liability Litigation, Case No. 1:14-cv-1748, MDL No. 2545, N.D. Ill.). The Honorable Matthew […]

By

Low-Testosterone Replacement Therapies Make Cover of Time Magazine: Are They Safe?

The topic of low testosterone (Low-T) replacement therapy drugs will be discussed, along with securing the coveted cover page, in the August 2014 issue of Time Magazine. The magazine will feature an article discussing the $2 Billion testosterone drug industry and detailing the safety concerns centered around Low-T replacement medications. This comes as no surprise […]

By

Transvaginal Mesh® Lawsuit Update: Defense Verdict in Favor of Boston Scientific in First Massachusetts State Court Trial

On July 29, 2014, a Massachusetts state court jury returned a verdict in favor of Boston Scientific over allegations that the company sold dangerous and defective transvaginal mesh (TVM) devices (Albright v. Boston Scientific Corp., Case No. 12-909, Middlesex County Superior Court, Massachusetts). Following nearly a three-week trial, Plaintiff Diane Albright’s design defect and failure […]

By

BMJ Investigation Shows Boehringer Ingelheim Withheld Critical Safety Information on Pradaxa®

Roger Denton of Schlichter, Bogard & Denton, LLP reports that the manufacturers of the blood thinning medication Pradaxa® withheld from regulators critical evidence on how monitoring drug plasma levels could have improved the drug’s safety, according to a recent BMJ Investigation. A recent article published in the British Medical Journal (BMJ) on July 23, 2014 […]

By

Xarelto® Surpassing Pradaxa® in Number of Adverse Event Reports, according to Recent ISMP Quarter Watch Report

According to the Institute for Safe Medication Practices’ (ISMP) most recent Quarter Watch Report, Xarelto® (rivaroxaban) has overtaken Pradaxa® (dabigatran) in the number of reported adverse events, including serious bleeding events. The ISMP reports that in 2013, the U.S. Food and Drug Administration (FDA) reported receiving 680 serious adverse event reports from individuals who alleged […]

By

The Las Vegas Herald: Las Vegas Judge Denies Attempt to Remove Her from Actos Case

The Las Vegas Herald reports that Judge Kerry Earley will not remove herself from a civil case filed by two women against Takeda Pharmaceuticals, the manufacturer of Actos. The Honorable Judge Earley stated, “I absolutely see no evidence that there’s any appearance of impropriety by me.” The Honorable Judge Earley made her ruling after attorney […]

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.